SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
09 avr. 2024 16h05 HE
|
Scynexis
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
28 mars 2024 16h01 HE
|
Scynexis
SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study...
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
30 janv. 2024 16h05 HE
|
Scynexis
JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
29 janv. 2024 17h15 HE
|
Scynexis
In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosisCombination of SCY-247 and...
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
05 janv. 2024 08h30 HE
|
Scynexis
JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13 nov. 2023 17h17 HE
|
Scynexis
IND enabling development activities for SCY-247, the next generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to advanceRemediation strategies following the voluntary recall of...
SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)
24 oct. 2023 08h00 HE
|
Scynexis
JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece
16 oct. 2023 08h00 HE
|
Scynexis
JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance
27 sept. 2023 20h31 HE
|
Scynexis
JERSEY CITY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME® (ibrexafungerp tablets) to the consumer level in the US...
SCYNEXIS to Participate in September Investor Conferences
28 août 2023 08h00 HE
|
Scynexis
JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...